BioXcel Therapeutics, Inc.
BTAINASDAQHealthcare● Active
$1.11
+$0.00(+0.00%)
Market Cap$34119748
P/E Ratio—
52W High$8.08
52W Low$1.01
BioXcel Therapeutics, Inc. (BTAI) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BTAI · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.54
Est. -$0.59 · +8.5%
Revenue
$0.00B
Est. $0.00B · -46.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 1-Quarter EPS Beat Streak
BTAI reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$93.32
Rev. $1001.5B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$93.32
Rev. Est.$1001.5B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.42 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 15, 2026 | -$0.59 | -$0.54 | +8.5% | $0.00B | $0.00B | -46.0% |
| ▼ Q1 FY2026 | Mar 26, 2026 | -$0.34 | -$0.58 | -70.6% | $0.00B | $0.00B | +69.0% |
| ▼ Q4 FY2025 | Nov 12, 2025 | -$1.54 | -$2.18 | -41.6% | $0.00B | $0.00B | -42.0% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -$2.30 | -$2.45 | -6.5% | $0.00B | $0.00B | -53.4% |
| ▲ Q2 FY2025 | May 12, 2025 | -$2.72 | -$1.50 | +44.9% | $0.00B | $0.00B | -52.0% |
| ▲ Q1 FY2025 | Mar 27, 2025 | -$4.36 | -$3.57 | +18.1% | $0.00B | $0.00B | -49.0% |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$8.00 | -$5.12 | +36.0% | $0.00B | $0.00B | -82.8% |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.42
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Beat
EPS Actual
-$0.54
EPS Est.
-$0.59
EPS Surpr.
+8.5%
Revenue
$0.00B
Q1 FY2026
Mar 26, 2026Miss
EPS Actual
-$0.58
EPS Est.
-$0.34
EPS Surpr.
-70.6%
Revenue
$0.00B
Q4 FY2025
Nov 12, 2025Miss
EPS Actual
-$2.18
EPS Est.
-$1.54
EPS Surpr.
-41.6%
Revenue
$0.00B
Q3 FY2025
Aug 12, 2025Miss
EPS Actual
-$2.45
EPS Est.
-$2.30
EPS Surpr.
-6.5%
Revenue
$0.00B
Q2 FY2025
May 12, 2025Beat
EPS Actual
-$1.50
EPS Est.
-$2.72
EPS Surpr.
+44.9%
Revenue
$0.00B
Q1 FY2025
Mar 27, 2025Beat
EPS Actual
-$3.57
EPS Est.
-$4.36
EPS Surpr.
+18.1%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$5.12
EPS Est.
-$8.00
EPS Surpr.
+36.0%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.26 | $-0.26 | $-0.26 | 1 |
| Q3 FY2027 | $-0.26 | $-0.26 | $-0.26 | 1 |
| Q2 FY2027 | $-0.29 | $-0.29 | $-0.29 | 1 |
| Q1 FY2027 | $-0.31 | $-0.31 | $-0.31 | 1 |
| Q4 FY2026 | $-0.41 | $-0.41 | $-0.41 | 1 |
| Q3 FY2026 | $-0.47 | $-0.47 | $-0.47 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 15, 2026 | +8.5% | $1.21 | $1.14 | -5.79% |
| ▼ Q1 FY2026 | Mar 26, 2026 | -70.6% | $1.43 | $1.37 | -4.20% |
| ▼ Q4 FY2025 | Nov 12, 2025 | -41.6% | $2.02 | $1.71 | -15.35% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -6.5% | $6.40 | $6.80 | +6.25% |
| ▲ Q2 FY2025 | May 12, 2025 | +44.9% | $1.53 | $1.48 | -3.27% |
| ▲ Q1 FY2025 | Mar 27, 2025 | +18.1% | $2.18 | $2.31 | +5.96% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +36.0% | $9.90 | $8.33 | -15.86% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +72.4% | $14.72 | $15.36 | +4.35% |
Q2 FY2026-5.79%
Report Date
May 15, 2026
EPS Beat/Miss
+8.5%
Price Before
$1.21
Price After
$1.14
Q1 FY2026-4.20%
Report Date
Mar 26, 2026
EPS Beat/Miss
-70.6%
Price Before
$1.43
Price After
$1.37
Q4 FY2025-15.35%
Report Date
Nov 12, 2025
EPS Beat/Miss
-41.6%
Price Before
$2.02
Price After
$1.71
Q3 FY2025+6.25%
Report Date
Aug 12, 2025
EPS Beat/Miss
-6.5%
Price Before
$6.40
Price After
$6.80
Q2 FY2025-3.27%
Report Date
May 12, 2025
EPS Beat/Miss
+44.9%
Price Before
$1.53
Price After
$1.48
Q1 FY2025+5.96%
Report Date
Mar 27, 2025
EPS Beat/Miss
+18.1%
Price Before
$2.18
Price After
$2.31
Q4 FY2024-15.86%
Report Date
Nov 14, 2024
EPS Beat/Miss
+36.0%
Price Before
$9.90
Price After
$8.33
Q3 FY2024+4.35%
Report Date
Aug 6, 2024
EPS Beat/Miss
+72.4%
Price Before
$14.72
Price After
$15.36
Avg Beat Reaction-2.92%
Avg Miss Reaction-4.43%
Beat Rate5 / 8 quarters
Largest Move-15.86% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BTAI ends December
BioXcel Therapeutics, Inc. (BTAI) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.54 — beating the analyst consensus of $-0.59 by +8.5%. The next BTAI earnings date is expected around September 1, 2026.
Each quarter, investors track BTAI earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BTAI revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BTAI's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BTAI earnings · 5 questionsBioXcel Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. BTAI typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BTAI historically reports after market close (AMC).
BTAI earnings datewhen is BTAI earningsBTAI next earnings datewhen does BTAI report earningsBTAI earnings calendar
▸ Source: FMP · BioXcel Therapeutics, Inc. SEC filings · US GAAP · BioXcel Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026